Pluristem Therapeutics (PSTI) News Today → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free PSTI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNBRVF Nabriva Therapeutics plcseekingalpha.com - August 18 at 10:08 PMPluri CEO Issues Shareholder Updatefinance.yahoo.com - July 25 at 8:14 AMPluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industriesbenzinga.com - July 25 at 2:34 AMPluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industriesfinance.yahoo.com - July 25 at 1:25 AMPluristem (PSTI) Phase III Study Misses Goal, Stock Downfinance.yahoo.com - July 14 at 4:41 PMPluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgeryfinance.yahoo.com - July 13 at 5:38 PMPluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary Goalmarkets.businessinsider.com - July 13 at 7:28 AMPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgeryfinance.yahoo.com - July 13 at 7:28 AMPluristem: Fiscal Q3 Earnings Snapshotapnews.com - May 10 at 2:20 PMPluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnershipfinance.yahoo.com - March 28 at 7:49 AMPluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trialseekingalpha.com - March 23 at 6:10 PMPluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusionsfinance.yahoo.com - March 23 at 8:52 AMPluristem Therapeutics, Inc. Common Stock (PSTI)nasdaq.com - March 21 at 8:40 AMPluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venturefinance.yahoo.com - March 8 at 9:53 AMPluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platformfinance.yahoo.com - February 24 at 8:48 AMThinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?marketwatch.com - January 12 at 10:49 PMPluristem Therapeutics (NASDAQ:PSTI) Downgraded to "Hold" at Zacks Investment Researchmarketbeat.com - January 12 at 8:04 AMIsrael's Tnuva partners with Pluristem to develop cultured cell-based meatmsn.com - January 10 at 1:04 PMBiotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platformfinance.yahoo.com - January 10 at 1:04 PMPluristem Climbs On Collaboration With Tnuva Of Israel For Commercialization Of Alternative Meatnasdaq.com - January 10 at 1:04 PMPluristem jumps 31% on collaboration with Tnuva to develop cultured cell-based food productsseekingalpha.com - January 10 at 8:04 AMBiotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platformfinance.yahoo.com - January 10 at 8:04 AMPluristem Therapeutics Inc Shares Fall 3.3% Below Previous 52-Week Low - Market Movernasdaq.com - December 30 at 9:58 AMPluristem Therapeutics Shares Tumble on Covid-19 Study Failure >PSTImarketwatch.com - December 29 at 12:57 AMPluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDSfinance.yahoo.com - December 28 at 2:56 PMPluristem: Phase II Studies Of ARDS Associated With COVID-19 Fails To Meet Primary Efficacy Endpointnasdaq.com - December 27 at 12:37 PMPluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19finance.yahoo.com - December 27 at 7:36 AMPluristem Therapeutics (NASDAQ:PSTI) Raised to "Buy" at Zacks Investment Researchmarketbeat.com - December 15 at 5:22 AMIs Pluristem Therapeutics (NASDAQ:PSTI) Using Too Much Debt?nasdaq.com - November 1 at 6:35 PMWill Pluristem Therapeutics (NASDAQ:PSTI) Spend Its Cash Wisely?finance.yahoo.com - September 1 at 3:26 PMIceCure Medical Ltd (ICCM.TA)ca.finance.yahoo.com - August 9 at 11:08 PMLongeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDSmarkets.businessinsider.com - July 29 at 3:24 PM Get Pluristem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter. Email Address What is Medicare Supplement Insurance? (Ad)Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. Learn More Here PSTI Media Mentions By Week PSTI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTI News Sentiment▼0.000.41▲Average Medical News Sentiment PSTI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTI Articles This Week▼00▲PSTI Articles Average Week Get Pluristem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CASI News INAB News ACHL News TARA News INKT News CYTH News SRZN News BCLI News WINT News PLUR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTI) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluristem Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
